STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial

Drugs called orexin agonists have been hailed for their ability to treat rare sleep disorders, but with new data, Alkermes is showing for the first time that the new class of therapies may benefit people with ADHD. In a randomized Phase 1 study…

Read the full story at STAT ↗